Ribbon-cutting included support from Mayor Wood of
South Salt Lake and other
dignitaries
SALT
LAKE CITY, April 12, 2024 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests, today
announced that it held the ribbon cutting event for its new
manufacturing facility yesterday in the City of South Salt Lake. The facility has been
designed to manufacture the Co-Dx Pro™ instrument and test cups for
the new platform*, as well as the Company's patented Co-Primers™
chemistry that underpins the Company's PCR diagnostic tests.
In attendance were South Salt Lake Mayor Cherie Wood and
other leaders and dignitaries, including Kelvyn Cullimore, the President and CEO of
BioUtah, an independent trade organization serving the Utah life sciences community and focused on
growing Utah into a global life
sciences leader.
Co-Dx CEO Dwight Egan, who spoke
at the event, remarked "This new facility represents a significant
step towards establishing Co-Diagnostics as a key player both in
the local community, and also on the international stage as we
pursue our mission of closing the access gap to high-quality,
equitable diagnostics that exists around the world. We are pleased
with the work that our team has put into bringing this facility
online and grateful for the support of Mayor Wood and other
community leaders."
"I am pleased Co-Diagnostics is establishing a manufacturing
campus in the City of South Salt
Lake. We are excited about their plans to add employees,
offer our residents quality jobs, and drive economic development in
the City On The Move," added Mayor Wood.
Kelyvn Cullimore of BioUtah commented, "We believe that
Co-Diagnostics' success over the past several years, which has
helped them to reach this noteworthy milestone, exemplifies the
entrepreneurial mindset of the state of Utah as a whole, as well as the attitude, work
ethic and vision that have contributed to the Utah life science industry being one of the 3
fastest growing in the country."
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™,
mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not yet available for
sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are
currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Forward-looking statements include
statements made with respect to our Co-Dx PCR platform and
forthcoming tests. Such forward-looking statements are based on
facts and conditions as they exist at the time such statements are
made and predictions as to future facts and conditions.
Forward-looking statements are subject to inherent uncertainties,
risks and changes in circumstances. Actual results may differ
materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-inaugurates-new-manufacturing-facility-in-utah-with-ribbon-cutting-event-302115272.html
SOURCE Co-Diagnostics